Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study [0.03%]
不可切除的III期EGFR突变型非小细胞肺癌患者接受同期放化疗后的体现实验、治疗模式和预后：一项全球真实世界研究的最终分析
Myung-Ju Ahn,Steven H Lin,Cheng-Ta Yang et al.
Myung-Ju Ahn et al.
Introduction: In the phase III LAURA study, osimertinib after definitive chemoradiotherapy (CRT) demonstrated a statistically significant, clinically meaningful progression-free survival (PFS) benefit over placebo in pati...
Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer [0.03%]
EGFR分型非小细胞肺癌患者胸水细胞学的预后价值
Naoya Ishibashi,Hideyuki Nagata,Ryuga Yabe et al.
Naoya Ishibashi et al.
Introduction: Positive pleural lavage cytology (PLC) indicates microscopic pleural dissemination and is associated with poor prognosis; however, it is not incorporated into the current TNM staging system and rarely guides...
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study [0.03%]
奥希替尼一线治疗后二线卡铂联合培美曲塞治疗EGFR突变型晚期NSCLC的真实世界预后：一项国际多中心队列研究
Igor Gomez-Randulfe,Federico Monaca,Ornella Cantale et al.
Igor Gomez-Randulfe et al.
Background: First-line osimertinib is one of the standards of care for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but most patients eventually progress. After progression, carboplatin plus pemetrexed remains...
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults [0.03%]
儿童肺癌的基因组特点：与成人相比，ALK融合及TP53突变频率较高
Michael Abele,Anton Karelin,Michaela Pogoda et al.
Michael Abele et al.
Background: Primary lung carcinomas are extremely rare in childhood, resulting in limited knowledge of their biology and potential therapeutic targets. Me...
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial [0.03%]
YK-029A治疗既往经治EGFR T790M突变NSCLC的I期临床试验的安全性和有效性：一项多中心研究
Xinyu Wu,Rui Wan,Lin Wu et al.
Xinyu Wu et al.
Introduction: YK-029A is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Previous studies have shown promising efficacy and tolerability in treatment-naïve patients with ...
Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies [0.03%]
艾乐替尼治疗后使用brigatinib的疗效和安全性：ALTA-2研究与J-ALTA研究综合分析
Tony Mok,Makoto Nishio,Tatsuya Yoshida et al.
Tony Mok et al.
Objectives: Alectinib is a first-line treatment for ALK + NSCLC. There is a lack of evidence guiding treatment after disease progression on alectinib. This integrated analysis of two phase 2 trials evaluated efficacy and ...
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers [0.03%]
新辅助奥希替尼和/或化疗治疗EGFR突变可切除非小细胞肺癌患者的疗效
Prashasti Agrawal,Julia Rotow,Gaetano Rocco et al.
Prashasti Agrawal et al.
Background: EGFR-inhibitors are currently not approved for neoadjuvant treatment of resectable EGFR-mutant non-small cell lung cancers (NSCLC). We report a real-world multi-institutional analysis of surgical and pathologi...
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity [0.03%]
帕博利尤单抗单药治疗PD-L1表达≥50%且身体状况不佳的晚期非小细胞肺癌患者的长期疗效：基于Transformer的AI技术解析预后复杂性
Alessio Cortellini,Edoardo Garbo,Giulia La Cava et al.
Alessio Cortellini et al.
Background: The use of first-line single agent immunotherapy in patients with advanced NSCLC and ECOG PS ≥ 2 remains controversial, as this frail population has been largely excluded from pivotal clinical trials. Real-wo...
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group [0.03%]
欧洲抗癌组织肺癌研究组牵头的泛欧洲多学科专家小组审议的临床病例：关于可手术切除的Ⅲ期非小细胞肺癌（NSCLC）临床试验收案定义的意见书
Mariana Brandão,Elena Prisciandaro,Eleni Xenophontos et al.
Mariana Brandão et al.
Introduction: Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease, leading to ambiguity in resectability criteria. This has prompted the EORTC Lung Cancer Group to establish a standardized definition o...
Reframing BALF liquid biopsy: Defining the BALF-plasma continuum for molecular diagnosis and early lung cancer management [0.03%]
重新定义BALF液体活检：界定BALF-血浆分子诊断和早期肺癌管理连续体
T Veerasatian,S K Rattanapitoon,C Thanchonnang et al.
T Veerasatian et al.